These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936 [TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview. Grossi P; Mohacsi P; Szabolcs Z; Potena L Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S1-4. PubMed ID: 26900989 [TBL] [Abstract][Full Text] [Related]
8. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Bonaros N; Mayer B; Schachner T; Laufer G; Kocher A Clin Transplant; 2008; 22(1):89-97. PubMed ID: 18217909 [TBL] [Abstract][Full Text] [Related]
9. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation. Valenza M; Czer LS; Pan SH; Aleksic I; Freimark D; Harasty DA; Admon D; Barath P; Blanche C; Trento A J Heart Lung Transplant; 1995; 14(4):659-65. PubMed ID: 7578172 [TBL] [Abstract][Full Text] [Related]
10. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study. Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781 [TBL] [Abstract][Full Text] [Related]
11. Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. DesJardin JA; Gibbons L; Cho E; Supran SE; Falagas ME; Werner BG; Snydman DR J Infect Dis; 1998 Dec; 178(6):1783-6. PubMed ID: 9815234 [TBL] [Abstract][Full Text] [Related]
12. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. Snydman DR; Werner BG; Heinze-Lacey B; Berardi VP; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS N Engl J Med; 1987 Oct; 317(17):1049-54. PubMed ID: 2821397 [TBL] [Abstract][Full Text] [Related]
13. CMV infections in bone marrow transplanted patients--evaluation of prophylaxis with Cytotect (CMV hyperimmuneglobulin). Zintl F; Färber I; Hermann J; Fuchs D; Prager J; Wutzler P Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):557-64. PubMed ID: 2480308 [TBL] [Abstract][Full Text] [Related]
14. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients. Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406 [TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus infections in heart and heart-lung transplant recipients. Wreghitt T J Antimicrob Chemother; 1989 Jun; 23 Suppl E():49-60. PubMed ID: 2550412 [TBL] [Abstract][Full Text] [Related]
16. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354 [TBL] [Abstract][Full Text] [Related]